Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Annals of Hematology|March 2, 2017
Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantationSebastian P Haen, Christiane Groh, Michael Schumm, et al.
Journal of Cancer Research and Clinical Oncology|February 18, 2017
Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignanciesSebastian P Haen, Vicky Eyb, Nora Mirza, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 12, 2016
Graft versus self (GvS) against T-cell autoantigens is a mechanism of graft-host interactionNora Mirza, Manfred Zierhut, Andreas Korn, et al.
Blood Advances|November 25, 2025
Predictive Capacity of Peri-Transplant Measurable Residual Disease Thresholds in NPM1-Mutant Acute Myeloid LeukemiaJan Schröder, Friederike Schwartz, Judith Metzdorf, et al.
Blood Advances|February 24, 2026
Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemiaJan Christian Schroeder, Friederike Schwartz, Judith Metzdorf, et al.
Msphere|August 21, 2020
Tracking of Antibiotic Resistance Transfer and Rapid Plasmid Evolution in a Hospital Setting by Nanopore SequencingSilke Peter, Mattia Bosio, Caspar Gross, et al.
Stem Cells Translational Medicine|January 4, 2013
Shared cell surface marker expression in mesenchymal stem cells and adult sarcomasStefan Wirths, Elke Malenke, Torsten Kluba, et al.
Haematologica|April 12, 2012
Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II studyBirgit Federmann, Martin Bornhauser, Christoph Meisner, et al.
Blood|June 10, 2010
Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 studyWolfgang A Bethge, Thoralf Lange, Christoph Meisner, et al.
Journal of Hematology & Oncology|August 16, 2023
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual diseaseJonas S Heitmann, Richard F Schlenk, Daniela Dörfel, et al.
Pageof 8